QuickView for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=FCF35C4030F3FEC70DEFC1231A3F8CE3;jsessionid=553E28A304991520DE1F8FA3A967F801;jsessionid=AF7582A47C461A8447D0520AB4C8AE0E;jsessionid=BF4D3366B0D7570E6183F0E480B46BD2;jsessionid=FE56FEBE50896BD9690DBC8DADA25FAC;jsessionid=B87B78ABD0B9B56AC1EA59E36899EE6D;jsessionid=D9DC0A39A89FD13E0E378E9C48EAC216;jsessionid=CBAD5CC9F781052289F6344E31B13733;jsessionid=0F6D23381B0ACDA0FF22D735D8548126 (gene)

No studies found

1. Biochemical characterization of mutants in chaperonin proteins CCT4 and CCT5 associated with heredit…
2. Role of CCT4/ErbB signaling in nephroblastoma: Implications for a biomarker of Wilms tumor.
3. Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair pro…
4. Transient Kinetic Analysis of ATP Hydrolysis by the CCT/TRiC Chaperonin.
5. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal sq…

There were no clinical trials for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=FCF35C4030F3FEC70DEFC1231A3F8CE3;jsessionid=553E28A304991520DE1F8FA3A967F801;jsessionid=AF7582A47C461A8447D0520AB4C8AE0E;jsessionid=BF4D3366B0D7570E6183F0E480B46BD2;jsessionid=FE56FEBE50896BD9690DBC8DADA25FAC;jsessionid=B87B78ABD0B9B56AC1EA59E36899EE6D;jsessionid=D9DC0A39A89FD13E0E378E9C48EAC216;jsessionid=CBAD5CC9F781052289F6344E31B13733;jsessionid=0F6D23381B0ACDA0FF22D735D8548126